VC  Vensana Capital

     Office Locations:

3601 W 76th St, Suite 20
Minneapolis, MN 55435
Phone: 612-217-8680

Get all office locations for this firm with a National Database subscription.


  • Early
  • Growth



  • Life Sciences & Healthcare
  • Medical Device



    Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Vensana is actively investing in late development and commercial stage companies across the medtech sector, including medical devices, diagnostics, drug delivery, digital health, and tech-enabled services. The firm expects to commit their $225 million inaugural fund to a dozen companies, with typical investments in the range of $10 million to $30 million. Vensana has 26 exits by IPO or M&A.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Amrinder Singh Principal
    Cynthia Yee Principal
    Greg Banker VP
    Justin Klein MD, JD Co-Founder & Managing Partner
    Kirk Nielsen Co-Founder & Managing Partner


    Recent Funding Events (trailing 12 months):










      Series B


      SpyGlass Ophthalmics



      Series B


    Portfolio companies include:


    Recent News: